References
Shord SS, Bressler LR, Tierney LA, Cuellar S, George A (2009) Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 66:999–1013. doi:10.2146/ajhp080455
Chau I, Cunningham D (2009) Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100:1704–1719. doi:10.1038/sj.bjc.6605061
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:534–536. doi:10.1016/S1470-2045(09)70112-3
Tol J, Cats A, Mol L et al (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26:393–397. doi:10.1007/s10637-008-9125-4
Baatar D, Jones MK, Tsugawa K et al (2002) Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: implications for angiogenesis and ulcer healing. Am J Pathol 161:1449–1457
Meza-Junco J, Wong C, Fields A, Sawer MB (2009) Esophageal ulcer in a patient who received bevacizumab. Invest New Drugs . doi:10.1007/s10637-009-9246-4
Kamba T, Tam BY, Hashizume H et al (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560–H576. doi:10.1152/ajpheart.00133.2005
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paiva, C.E., Maia, Y.C.P., Paiva, B.S.R. et al. Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab. Invest New Drugs 28, 882–883 (2010). https://doi.org/10.1007/s10637-009-9312-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9312-y